anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The mechanism of action of pimecrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that pimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it inhibits T cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and Interleukin-10 (Th2-type) cytokine synthesis in human T cells. In addition, pimecrolimus prevents the release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/IgE.
PROBLEM TO BE SOLVED: To clean teeth without damaging an organism and to easily infiltrate various chemicals into an interdental/periodontal tissue by arranging a feeding means feeding various chemicals to the dental/periodontal tissue and a sucking means sucking the material retained on the tissue. SOLUTION: A chemical is filled in a tubular feeding means 3, fine holes are provided on the tubular feeding means 3, and the chemical is discharged and fed to the outside from the holes. An outer skin 1 is a cord-like object connected to an external chemical feeding means 3. The feeding means 3 is inserted to a tooth 4, then it is squeezed by a feeding means position adjusting means 2 at a place where the chemical is to be fed. The chemical reaches the feeding means 3 from a chemical feeding means body through a tube passing in the outer skin 1 and is discharged and fed to a periodontal pocket. A syringe may be used as a driving means for sucking.
Participants randomized to the 60mcg group will receive 60mcg of dexmedetomidine sublingual film every 30 minutes, if they continue to have agitation and do not meet any cardiovascular stopping criteria. The maximum dosing for this arm is 240mcg.
The Enhanced Intervention Group was a subgroup of the participants that were invited for voluntary weekly meet-n-greet sessions in the Primary Care Clinic. These sessions were information and not educational sessions for the intervention. The entire EIG concept was to test a social component of participants by providing an informal opportunity for a DPPFit social group. The group sessions were terminated after only 5 weeks as a result of the Covid-19 pandemic. They were the only component of the DPPFit study that were face-to-face.
Participants with AML will receive Azacitidine 75 mg/m\^2 of BSA by SC injection or IV infusion prior to the start of AZD2811 infusion on Days 1 through 7 or for 5 consecutive weekdays (Days 1 through 5) with treatment holidays on the 2 weekend days (Days 6 and 7), and the remaining azacitidine dosing will be administered on the first 2 weekdays of the 2nd week (Days 8 and 9) of each 28-day cycle. Participants will receive IV infusion of AZD2811 Dose 2 on Days 1, 4, 15, and 18 of each 28-day cycle. Participants will receive the treatment until disease progression, unacceptable toxicity, or the decision to discontinue treatment by the participant or the study physician, whichever occurs first.
The present invention relates to antimicrobial compositions. Antiviral composition is characterized in that the titanium dioxide, silicon dioxide or barium sulfate nanoparticles sized to max. 200 nm, (2-hydroxy)propyl beta-cyclodextrin (HPBCD) aqueous solution, an excipient selected from a group containing sodium polyacrylate, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, poloxamer and auxiliary additives selected from a group containing glycerol, propylene glycol in following per cent ratio: Titanium dioxide or silicon dioxide or barium sulfate 0.05-5.0, HPBCD - 0.05-50, Excipient -0.1-20, Glycerol - 10-20, Purified water - up to 100. Antiviral composition is characterized in that the titanium dioxide, silicon dioxide or barium sulfate nanoparticles sized to max. 200 nm, (2-hydroxy)propyl beta-cyclodextrin (HPBCD) aqueous solution, an excipient selected from a group containing sodium polyacrylate, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, poloxamer, auxiliary additives selected from a group containing glycerol, propylene glycol, and paraffin oil in following per cent ratio: Titanium dioxide or silicon dioxide or barium sulfate - 0.05-5.0, HPBCD - 0.05-50, Excipient -0.1-20, Glycerol -10-20, Paraffin oil -1.0-2.0, Purified water - up to 100. Antiviral composition is characterized in that the titanium dioxide, silicon dioxide or barium sulfate nanoparticles sized to max. 200 nm, (2-hydroxy)propyl beta-cyclodextrin (HPBCD) aqueous solution, an excipient of polymeric origin selected from a group containing natural Sodium deoxyribonucleate (DNA) or gelatin and auxiliary additives selected from a group containing glycerol, propylene glycol in following per cent ratio: Titanium dioxide or silicon dioxide or barium sulfate -0.05-5.0, HPBCD -0.05-50, polymeric excipient -0.01-20, Glycerol -10-20, Purified water -up to 100. Nanocomposite formulations under the present invention reduce viral infections by a factor of 100, in vitro.
A mud cosmetic pack is provided to supply minerals from mineral materials, show health functionality of loess, and provide fiber from Artemisia princeps var. orientalis, and provide various vegetable nutrients such as cellulose and vitamin C, thereby showing skin calming effect and moisturizing effect, preventing pigment change of the skin and aging, and having enhanced health functionality such as sterilizing, blood circulation, and metabolism promoting effects. In a mud cosmetic pack comprising Artemisia princeps var. orientalis where 100 parts by weight of a loess cosmetic pack powder is mixed with 20-150 parts by weight of water in a mud form, the loess beauty pack powder consists of 50-80 wt.% of loess powder having a particle size of 10-500mum, 0.1-10 wt.% of dried and pulverized green tea powder, 5-20 wt.% of Artemisia princeps var. orientalis powder or poroligenous liquor of Artemisia princeps var. orientalis, 1-15 wt.% of at least one functional mineral material selected from the group consisting of pegmatite, elvan, germanium, and zeolite, 1-10 wt.% of a thickening agent, 0.1-5 wt.% of a water soluble polymer selected from the group consisting of polyvinylpyrrolidone, polyvinylalcohol, and carboxymethylcellulose, and 0.1-1 wt.% of vitamin C and vitamin E.
The present invention discloses a degradable polymer microcapsule injection of water-solubility drugs and a preparation method thereof. Polysaccharide, polylactic acid and medical level poly lactic acid are used as coating materials, wherein the polysaccharide and the polylactic acid contain double bond and have good biocompatibility and biodegradability. Through controlling the proportion of a mixture of the polysaccharide and the poly lactic acid, the W/O/W emulsion polymerization technology is adopted, and thus, drug microcapsule type injection with the particle diameter of 100 to 2000 nm is prepared. The coating material of the present invention is a derivative of poly lactic acid and dextran, and thus, the coating material has no poison, biodegradability and good biocompatibility. The present invention has good storage stability, and the drug release performance of the injection can be adjusted through various methods. The present invention has the advantages of simple manufacturing technology and strong repetitiveness, and is suitable for preparing various water-solubility drug injections.
Depression is a common mental health disorder, and in recent years, the incidence of various forms of depression has been on the rise. Most medications for depression are highly dependency-inducing and can lead to relapse upon discontinuation. Therefore, novel treatment modalities and therapeutic targets are urgently required. Traditional Chinese medicine (TCM) offers advantages in the treatment of depression owing to its multi-target, multi-dimensional approach that addresses the root cause of depression by regulating organ functions and balancing Yin and Yang, with minimal side effects. Cynaroside (CNS), an extract from the traditional Chinese herb honeysuckle, is a flavonoid compound with antioxidant properties. In this study, network pharmacology identified 44 potential targets of CNS associated with depression and several highly correlated inflammatory signaling pathways. CNS alleviated LPS-induced M1 polarization and the release of inflammatory factors in BV-2 cells. Transcriptomic analysis and validation revealed that CNS reduced inflammatory polarization, lipid peroxidation, and ferroptosis via the IRF1/SLC7A11/GPX4 signaling pathway. In vivo experiments showed that CNS treatment had effects similar to those of fluoxetine (FLX). It effectively ameliorated anxiety-, despair-, and anhedonia-like states in chronic unpredictable mild stress (CUMS)-induced mice and reduced microglial activation in the hippocampus. Thus, we conclude that CNS exerts its therapeutic effect on depression by inhibiting microglial cells from polarizing into the M1 phenotype and reducing inflammation and ferroptosis levels. This study provides further evidence that CNS is a potential antidepressant, offering new avenues for the treatment of depression.
HSCT: Adult and Pediatric Patients 12 Years of Age and Older and Weighing at least 30 kg

The recommended dosage of PREVYMIS is 480 mg administered orally or intravenously once daily. When PREVYMIS is administered orally, the recommended dosage is one 480 mg tablet once daily or two 240 mg tablets once daily. Four 120 mg packets of oral pellets once daily can be used for patients who cannot swallow tablets [see Dosage and Administration (2.9)]. For preparation and administration instructions of intravenous dosing refer to instructions in subsection 2.10 [see Dosage and Administration (2.10)]. For pediatric patients less than 12 years of age or weighing less than 30 kg, refer to weight-based dosing in Table 1 and Table 2 [see Dosage and Administration (2.5)].

Initiate PREVYMIS between Day 0 and Day 28 post-HSCT (before or after engraftment) and continue through Day 100 post-HSCT. In patients at risk for late CMV infection and disease, PREVYMIS may be continued through Day 200 post-HSCT [see Clinical Studies (14.2)].

Dosage of PREVYMIS should be adjusted when co-administered with cyclosporine [see Dosage and Administration (2.4)].

Kidney Transplant: Adult and Pediatric Patients 12 Years of Age and Older and Weighing at least 40 kg

The recommended dosage of PREVYMIS is 480 mg administered orally or intravenously once daily. When PREVYMIS is administered orally, the recommended dosage is one 480 mg tablet once daily or two 240 mg tablets once daily. Four 120 mg packets of oral pellets once daily can be used for patients who cannot swallow tablets [see Dosage and Administration (2.9)]. For preparation and administration instructions of intravenous dosing refer to instructions in subsection 2.10 [see Dosage and Administration (2.10)].

Initiate PREVYMIS between Day 0 and Day 7 post-transplant and continue through Day 200 post-transplant.

Dosage of PREVYMIS should be adjusted when co-administered with cyclosporine [see Dosage and Administration (2.4)].
###  Adenocarcinoma of the Breast or Ovary

The recommended dose of thiotepa for injection for treatment of adenocarcinoma of the breast or ovary is 0.3 to 0.4 mg/kg intravenously. Doses should be given at 1 to 4 week intervals. Initially the higher dose in the given range is commonly administered. The maintenance dose should be adjusted weekly on the basis of pretreatment control blood counts and subsequent blood counts. Maintenance doses should not be administered more frequently than weekly.

###  Malignant Effusions

The recommended dose of thiotepa for injection for treatment of malignant effusions is 0.6 to 0.8 mg/kg intracavitary. Administration is usually effected through the same tubing which is used to remove the fluid from the cavity involved. Doses should be given at 1 to 4 week intervals. Initially the higher dose in the given range is commonly administered. The maintenance dose should be adjusted weekly on the basis of pretreatment control blood counts and subsequent blood counts. Maintenance doses should not be administered more frequently than weekly.

###  Superficial Papillary Carcinoma of the Urinary Bladder

The recommended dose of thiotepa for injection for treatment of superficial papillary carcinoma of the urinary bladder is 60 mg in 30 to 60 mL of Sodium Chloride Injection into the bladder by catheter. The solution should be retained for 2 hours. If the patient finds it impossible to retain 60 mL for 2 hours, the dose may be given in a volume of 30 mL. The patient may be repositioned every 15 minutes for maximum area contact. The usual course of treatment is once a week for 4 weeks. The course may be repeated if necessary, but second and third courses must be given with caution since bone-marrow depression may be increased.

Pediatric use information is approved for Adienne SA’s TEPADINA (thiotepa) for Injection. However, due to Adienne SA’s marketing exclusivity rights, the drug product is not labeled with that information.
Pancreatic cancer is very difficult to detect and treat, and patients with this cancer generally live fewer years than patients with other types of cancer. Part of the reason why pancreatic cancer is so hard to treat is because it is usually discovered when it is too advanced to be able to treat. The goal of this protocol is to find a way to detect pancreatic cancer earlier, when it is still treatable in order to improve the survival of patients.

The pancreas is a gland which produces digestive juices that mix with food in the intestines. Normal patients as well as patients with pancreatic cancer produce these juices. Other researchers have collected this fluid from very small numbers of patients and their results suggest that pancreatic fluid can be used to detect pancreatic cancer. One of the major issues with these results is that pancreatic fluid from only a very few number of patients has been collected and analyzed. In order to find out whether the pancreatic fluid can be used as a standard test for pancreatic cancer, the fluid from a greater number of patients needs to be analyzed. Also, of all the different chemicals in the pancreatic fluid, in this study we will try to figure out what the most important chemicals are in diagnosing pancreatic cancer.
Objective: The aim of the study was to characterize artificial stones used for research in endourology in terms of radiological properties and hardness, based on stone fragmentation, and to compare them with real stones. Materials and Methods: We built artificial stones using BegoStone Plus™ powder (BEGO, Lincoln, RI), with powder (g)-water (mL) ratios ranging from 15:03 to 15:12. The CT Gemstone Spectral Imaging Software® (GE Medical Systems, LLC, Waukesha, WI) was used to evaluate the radiological density in HU and spectral properties. Stone fragmentation was assessed in an in vitro experimental setting. These properties of artificial stones were compared with real urinary calculi. Results: Regarding radiological density in terms of HUs, 15:03 artificial calculi showed similar results when compared with real stones comprising calcium oxalate and calcium phosphate. The 15:03 and 15:04 artificial stones showed similar spectral property results to calcium pyrophosphate stones. The 15:11 artificial stones showed similar stone fragmentation results to real stones comprising uric acid, and 15:03 artificial calculi showed similar results to apatite and cystine stones. Conclusions: Artificial stones are useful for research in endourology. Stones with a powder (g)-water (mL) ratio of 15:03 proved to mimic real hard stones in terms of HUs, atomic number, and stone fragmentation in our study and could be used as artificial hard stones, and 15:11 stones showed similar stone fragmentation to uric acid stones. Our study might suggest that standard Bego stones are useful to investigate different areas in endourology, but not radiological properties because radiological homogeneity is not ensured unless more sophisticated mixing methods are used.
This project aims to include patients enrolled in PACE organizations or other healthcare organizations serviced by TRHC. PGx testing will be performed by a vendor contracted by TRHC (CLIA certified). Genetic testing for CYP450 isoforms like CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A5, and transporters like SLCO1B1, ABCB1, and ABCG2 will be conducted, along with other genes in individual vendors' testing panel. The results will be integrated into TRHC's proprietary CDSS (Medication Risk Mitigation Matrix, Tabula Rasa Healthcare, Moorestown, NJ). Phenotypes related to CYP450 isoforms will be used to guide pharmacists to identify drug-drug interactions (DDIs), drug-gene interactions (DGIs), and drug-drug-gene interactions (DDGIs).(16) Clinical pharmacists will translate PGx results combined with a comprehensive DDI review into actionable clinical recommendations. Prescribers will review the pharmacist's recommendation, and based on their clinical assessment will decide whether or not to implement the therapy recommendation. Endpoints like number and type of pharmacist recommendations and uptake by physicians, follow-up drug regimens, and outcomes will be collected for up to 12 months \[baseline (data from the previous year), 3, 6 and 12 months post-PGx intervention\] for each patient to get a longitudinal perspective of implementing PGx into CDSS systems.
Anaesthesia was induced by sevoflurane in oxygen. Cisatracurium 0.15 mg kg-1 was administered after loss of the lash reﬂex, then ventilated manually until the amplitude of T1 decreased to 0. Intubation was performed and switched to mechanical ventilation with a fresh gas flow of 2 L min-1. Anesthesia was maintained by sevoflurane or sevoflurane+60% nitrous oxide respectively. The surgical incision was performed at least 30 min after tracheal intubation, provided that the predetermined end-tidal sevoflurane concentration had been constant for at least 30 min and that the difference between inspired and end-tidal concentrations was less than 10%.

Brain electrical activity was measured using Narcotrend Monitor and S/5 Compact Anaesthesia Monitor, which displayed unprocessed EEG and burst suppression ratio, respectively. The design of the experiment is referred to the "Dixon up-and-down" method. To avid anaesthesia awareness, the first subject was designed to receive end-tidal sevoflurane concentration of 2.5 %. The presence or absence of isoelectric EEG (Entropy Module) of the preceding patient determined the end-tidal concentration of sevoflurane given to the next patient (with an increment size of 0.2%). The isoelectric EEG was considered as significant when the isoelectric state last for more than 1 min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached.
BACKGROUND: Previous studies showed that preoperative opioid use is associated with increased postoperative opioid use and surgical site infection (SSI) in patients undergoing ventral hernia repair (VHR). Orthopedic surgery literature cites increased resource utilization with opioid use. This study aimed to determine the effect of preoperative opioid use on resource utilization after open VHR.
METHODS: A retrospective institutional review board-approved study of VHRs from a single tertiary care practice between 2013 and 2020 was performed. Medical records, the National Surgical Quality Improvement Program database, and Kentucky All Schedule Prescription Electronic Reporting data were reviewed for patient demographics, comorbidities, dispensed opiate prescriptions, hernia characteristics, and outcomes. Univariate logistic regression analyses assessed the effect of each patient's demographic and clinical characteristics. Multivariate logistic regression models analyzed significant factors from the univariate analyses. The primary outcome was resource utilization measured as readmission, emergency department visit, or >2 postoperative clinic visits within 45 days after VHR.
RESULTS: Overall, 381 patients who underwent VHR were identified; of which 101 patients had preoperative dispensed opioids. Multivariate analysis demonstrated that patient gender at birth, any new-onset SSI, and any preoperative opioid use were associated with increased postoperative resource utilization (odds ratio, 1.76; P = .026).
CONCLUSION: Preoperative opioid use was determined as a risk factor that increased resource utilization after open VHR. An understanding of the drivers of the increased use of resources is essential in developing strategies to improve healthcare value. Future research will focus on strategies to reduce the utilization of resources among patients who use opioids.
Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
Vascular occlusion is directly related with life. Blood circulation disorders are correlated with various diseases, but conventional treatment methods in the hospitals cannot provide a sufficient solution. Use of aspirin, warfarin, heparin or urokinase causes many side reactions and problems of copious bleeding and a risk of death from overdose. Therefore, there is a need for a novel blood circulation enhancer or a method for unclogging blood vessels which can solve or reduce the problems. The present inventors have conducted many studies for 4.5 years to provide the solution from medicinal herbs and foods. The present invention is based on use of foods. It is shown that a food composition including 20% of apple powder, 40% of walnut power, 40% of ginger powder, 5% of Gastrodia elata BLUME powder, 10% of lotus root powder, 5% of carrot powder and 5% of potato powder (the content of each ingredient may be controlled depending on severity of a condition) shows an excellent effect and safety, as determined from many test and treatment processes. Therefore, the food composition can be commercialized and provide advantageous effects in the market of blood circulation enhancement and blood vessel unclogging.
Treatment modalities in patients with thalassemia include long-term transfusion therapy, iron chelation, splenectomy, allogeneic hematopoietic transplantation and supportive measures. Attempts to downgrade the systemic proinflammation and thereby reducing the morbidity of the disease warrants investigation in patients with β-thalassemia (TM-β). In blood disorders, as with most other diseases, achieving and maintaining inflammatory homeostasis is essential and necessary for survival. Both TM and gingival diseases cause increased levels of pro-inflammatory cytokines in the body fluids. Moreover, higher prevalence of gingival diseases is reported in children with TM. With oral hygiene maintenance and care, down-regulation of the systemic burden of the disease might be attained which will subsequently aid in achieving reduced morbidity in children with TM.

Both the groups will receive non surgical periodontal therapy (scaling and root planing) with the chlorhexidine containing adjunct in the form of a mouthrinse. Additionally, they will be taught standard tooth brushing technique (Fones technique). Participants will receive both verbal instructions and practical demonstrations.